Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient

In recent years, the evolution of treatments has made it possible to significantly improve the outcomes of patients with non-small cell lung cancer (NSCLC). In particular, while molecular targeted therapies are effective in specific patient sub-groups, immune checkpoint inhibitors (ICIs) have greatl...

Descripción completa

Detalles Bibliográficos
Autores principales: Rossi, Giovanni, Russo, Alessandro, Tagliamento, Marco, Tuzi, Alessandro, Nigro, Olga, Vallome, Giacomo, Sini, Claudio, Grassi, Massimiliano, Dal Bello, Maria Giovanna, Coco, Simona, Longo, Luca, Zullo, Lodovica, Tanda, Enrica Teresa, Dellepiane, Chiara, Pronzato, Paolo, Genova, Carlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281184/
https://www.ncbi.nlm.nih.gov/pubmed/32365882
http://dx.doi.org/10.3390/cancers12051125

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281184/
https://www.ncbi.nlm.nih.gov/pubmed/32365882
http://dx.doi.org/10.3390/cancers12051125

Ejemplares similares